NLS drug-2

AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma. The decision was made due to substantially increased enrolment timelines and low event rates, respectively, which made it prohibitive to deliver study results within a timeframe to meaningfully advance clinical practice. STABILIZE-CKD and DIALIZE-Outcomes STABILIZE-CKD and DIALIZE-Outcomes trials are part […]

Valo Therapeutics received approval from Germany’s PEI (Paul Ehrlich Institute) to extend the tumor types to be treated in the company’s current Phase I trial into two subtypes of sarcoma. “This extension of the study into sarcoma is significant as it broadens the range of patients we can recruit into our PeptiCRAd-1 study. These sub-types […]

Alzinova has reported positive top-line results from its phase 1b clinical trial of the vaccine candidate ALZ-101 in Alzheimer’s disease. “The positive top-line results further strengthen our confidence in that ALZ-101 can become a unique therapeutic vaccine and thus help patients suffering from Alzheimer’s disease and their families to a better life. Alzinova has the […]

The company has announced data from part 2 of its international multi-center CORIST open label phase IIa trial. The 25 enrolled patients in CORIST part 2 were heavily pretreated and no other active treatment options were available. The data documents long survival for wild type KRAS patients with metastatic colorectal cancer (mCRC) participating in the […]

The company has announced positive results from its Phase 1a clinical trial in healthy subjects. The clinical trial demonstrated favorable safety and tolerability, fast uptake of HER-096, and significant HER-096 concentrations in the cerebrospinal fluid (CSF) after a single subcutaneous injection, states the company in a press release. “We are very pleased with the topline […]

FluoGuide has reported positive topline efficacy and safety results in the trial with the lead product FG001 for guiding surgery in aggressive brain cancer (high-grade glioma). “I am pleased with this first result of FG001 efficacy in aggressive brain cancer. Here is a promising drug and we should now define the best use of it […]